Unverricht-lundborg Syndrome
Disease Details
Family Health Simplified
- Description
- Unverricht-Lundborg syndrome is a rare, inherited form of progressive myoclonic epilepsy characterized by myoclonic seizures, tonic-clonic seizures, and progressive neurological decline.
- Type
- Unverricht-Lundborg syndrome is a type of progressive myoclonus epilepsy. It is inherited in an autosomal recessive manner.
- Signs And Symptoms
- Patients with Unverricht–Lundborg disease exhibit myoclonic jerks and tonic-clonic seizures at a young age, between ages 6–16. The myoclonic jerks occur in the muscles of the arms and legs closest to the torso, and are triggered due to a variety of common external stimuli. Seizures begin at an average age of 10.8 years, with myoclonus beginning around 12.1 years. It is not currently possible to diagnose without a genetic test, and since early symptoms are general, it is often mistaken for another more common epilepsy, in many cases juvenile myoclonic epilepsy (JME). These episodes of myoclonus may be caused by physical exertion, stress, light, or other stimuli. Within 5-10 years, these episodes may increase in severity to the point that they interfere with everyday activities such as walking. Individuals with Unverricht-Lundborg disease also often experience seizures involving muscle rigidity, convulsions, and loss of consciousness; these may also increase in frequency as the disease progresses but may be controlled with treatment. After several years, these seizures may stabilize or decrease in frequency. Eventually, people with Unverricht-Lundborg disease may develop ataxia, intention tremor, dysarthria, depression, and a slow, mild decline in intellectual functioning.
- Prognosis
- For early Unverricht–Lundborg disease patients, the disease would begin to progress early and lack of effective treatment meant a quick progression. In many cases the patient would require a wheelchair for mobility, and would die at a young age.However, increased knowledge about the disease and improved treatment and medication has led to a dramatic improvement in prognosis for individuals with ULD. Antiepileptic drugs reduce the occurrence of seizures and myoclonus, which leads to a decrease in the damage caused in the brain due to seizures and the body due to falls resulting from the seizures. As a result, individuals with Unverricht–Lundborg disease are now much less likely to end up in a wheelchair, which eliminates the chance of complications involved with being a wheelchair user. All these factors have increased the outlook for patients. Due to the progressive nature of the disease, depression is prevalent, but support of family and friends as well as proper treatment can help. While early patients with ULD had a life expectancy of around 24 years, there have recently been reported cases of individuals living to near-normal ages.
- Onset
- Unverricht-Lundborg syndrome, a form of progressive myoclonic epilepsy, typically has an onset in childhood or early adolescence, generally between the ages of 6 and 15.
- Prevalence
- Unverricht-Lundborg syndrome, also known as progressive myoclonus epilepsy type 1 (EPM1), is considered a rare condition. Its prevalence is estimated to be around 1 to 9 per 100,000 individuals, although it varies depending on the geographic region, with higher rates observed in certain areas such as Finland.
- Epidemiology
- The only country that Unverricht–Lundborg disease has a reported incidence is in Finland, where it is reported to occur in 4 in 100,000 individuals. However, ULD has only become well defined recently, and it is likely still under diagnosed, so the actual incidence may be different that what is currently known. Other countries with known cases include countries in the Mediterranean region including Italy, France, Tunisia, Algeria, and Morocco, next is Czech Republic as well as the United States.
- Intractability
- Unverricht-Lundborg Syndrome (ULS) is often considered intractable, as it is a form of progressive myoclonus epilepsy that is usually difficult to control with standard antiepileptic drugs. While some patients may achieve partial seizure control with medications, complete control is rarely achieved, and the condition tends to be chronic and progressive.
- Disease Severity
- Unverricht-Lundborg syndrome is a form of progressive myoclonus epilepsy. The severity of this disease varies among individuals. Most people experience worsening myoclonus (involuntary muscle jerks) and epilepsy over time, which can significantly impact daily activities and quality of life. However, with appropriate treatment, many patients can manage symptoms and maintain a reasonable level of function.
- Healthcare Professionals
- Disease Ontology ID - DOID:3535
- Pathophysiology
- Unverricht-Lundborg syndrome (ULS) is a type of progressive myoclonic epilepsy. The pathophysiology involves mutations in the CSTB gene, which encodes cystatin B, a protein that inhibits cysteine proteases. Deficiency of cystatin B leads to increased protease activity, resulting in neuronal degeneration and gliosis, particularly in the cerebellum and cerebral cortex. This contributes to the characteristic symptoms of myoclonus, seizures, and progressive neurological decline.
- Carrier Status
- Unverricht-Lundborg Syndrome (ULS) is inherited in an autosomal recessive manner, meaning that an affected individual must inherit two copies of the mutated gene, one from each parent. Carriers, who have only one copy of the mutated gene, usually do not exhibit symptoms of the disease.
- Mechanism
- While the genetic cause of Unverricht–Lundborg disease is known, the mechanism by which it works is not fully known. Current research has provided promising results that may lead to a confirmation of the mechanism. This research has been performed on mice with the gene for producing cystatin B removed, to provide a similar set of symptoms to individuals with ULD. The mechanism currently supported by research is very similar to another theory of epilepsy progression known as kindling.
- Treatment
- While there is no current cure to repair the mutated CSTB gene, several antiepileptic drugs are effective in reducing seizures and helping patients with ULD to manage the symptoms. In addition, new research is being performed to examine the effectiveness of other types of treatments.
- Compassionate Use Treatment
-
Unverricht-Lundborg syndrome (ULS), also known as progressive myoclonus epilepsy type 1 (EPM1), primarily requires management through conventional antiepileptic drugs. When considering compassionate use or off-label treatments:
1. **Compassionate Use Treatments**: These are treatments that are not yet approved for general use but may be provided to patients with serious conditions when no comparable or satisfactory alternatives are available. For ULS, such treatments could include investigational drugs that have shown promise in clinical trials but are not yet fully approved.
2. **Off-Label Treatments**: Clinicians might prescribe medications such as:
- **Zonisamide**: Although approved specifically for partial seizures, its use can help manage myoclonic seizures in ULS.
- **Levetiracetam**: Commonly used for epilepsy, this drug may help reduce myoclonic seizures in ULS patients.
- **Piracetam**: Though primarily a nootropic, it has been used off-label to manage myoclonus.
3. **Experimental Treatments**: These might involve participation in clinical trials exploring new medications or therapies aimed at better controlling seizures or slowing disease progression.
It is essential for patients to discuss these options with their healthcare providers to understand the potential benefits and risks. - Lifestyle Recommendations
-
Unverricht-Lundborg syndrome is a type of progressive myoclonic epilepsy. Here are some lifestyle recommendations for managing the condition:
1. **Medication Adherence:**
- Strictly follow the prescribed medication regimen to control seizures and myoclonus.
2. **Avoid Seizure Triggers:**
- Identify and avoid potential triggers such as stress, sleep deprivation, or abrupt changes in lighting.
3. **Regular Sleep:**
- Maintain a regular sleep schedule to help manage the frequency and severity of seizures.
4. **Healthy Diet:**
- Follow a balanced diet and avoid excessive caffeine and alcohol, which can exacerbate symptoms.
5. **Physical Activity:**
- Engage in regular, moderate exercise tailored to one's abilities to help improve overall health and reduce stress. Avoid activities that can induce seizures or myoclonus.
6. **Support System:**
- Build a support network of family, friends, and health professionals for emotional and practical support.
7. **Regular Check-Ups:**
- Keep regular appointments with healthcare providers for ongoing management and adjustments in treatment plans.
8. **Education and Employment:**
- Seek accommodations if necessary to manage the impact of the condition on education or employment.
9. **Stress Management:**
- Practice stress-relief techniques such as mindfulness, meditation, or yoga to help reduce seizure frequency.
10. **Safety Measures:**
- Take precautions to prevent injuries during seizures, such as using protective headgear if necessary and ensuring a safe living environment. - Medication
-
Unverricht-Lundborg syndrome, a type of progressive myoclonus epilepsy, is often treated with a combination of medications to manage symptoms. Commonly used medications include:
1. Valproic acid (Depakote) - often the first line of treatment to control seizures and myoclonus.
2. Clonazepam (Klonopin) - may be used to help with myoclonus.
3. Levetiracetam (Keppra) - increasingly used for its broad-spectrum antiepileptic properties and fewer side effects.
Avoid drugs that can worsen myoclonus, such as phenytoin or carbamazepine. Treatment is usually tailored to the individual's response and tolerability. Regular follow-ups with a neurologist specializing in epilepsy are essential for optimal management. - Repurposable Drugs
- No specific repurposable drugs for Unverricht-Lundborg syndrome are well-established in current medical literature. This rare form of progressive myoclonic epilepsy is typically managed with medications primarily used for seizure control, such as valproic acid, clonazepam, and levetiracetam. Research is ongoing to find more effective treatments.
- Metabolites
- Unverricht-Lundborg syndrome (ULS) is a form of progressive myoclonus epilepsy. Specific metabolites associated with the condition have not been extensively documented. However, studies have indicated abnormalities in oxidative stress markers and neurotransmitter metabolism. There is not enough data to definitively list particular metabolites consistently altered in ULS.
- Nutraceuticals
-
For Unverricht-Lundborg Syndrome (also known as Progressive Myoclonic Epilepsy type 1), there is limited evidence directly supporting the use of specific nutraceuticals. Nutraceuticals are food-derived products that provide health benefits, including the prevention and treatment of disease. While general dietary recommendations and managing overall health are important, it's crucial to consult a healthcare provider for tailored advice.
Currently, there is no established research indicating that nanotechnology-based treatments (like nanoparticles) are being used for Unverricht-Lundborg Syndrome. Traditional treatment typically involves anti-epileptic drugs and supportive care to manage symptoms. - Peptides
- Unverricht-Lundborg syndrome, also known as Baltic myoclonus, is a type of progressive myoclonic epilepsy. It is caused by mutations in the CSTB gene, which encodes the cystatin B protein. Peptides and nanoparticles (nan) are not standard treatments or diagnostic tools for this condition. Instead, management typically includes antiepileptic medications like valproate or clonazepam to control seizures and myoclonus. Peptides related to cystatin B might be of theoretical interest in research but are not currently part of clinical practice for this syndrome.